ERBB2 and sarcoma: A few antigens have been targeted in pre-clinical and clinical settings to generate anti-OS CAR molecules, including human epidermal growth factor receptor-2 (HER-2), which was shown to be safe and well tolerated in a Phase I sarcoma basket trial14.